TapewireFind a company

person · Reporting owner

Aynechi Tiba

Disclosed activity across 5 companies

Tapewire entity
40954
SEC CIK
0001669220

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
MBX Biosciences, Inc.MBX · Entity 4247DirectorJune 04, 2026June 05, 2026
Mirum Pharmaceuticals, Inc.MIRM · Entity 2416DirectorJuly 17, 2019July 17, 2019
Nkarta, Inc.NKTX · Entity 6346DirectorJune 08, 2022June 10, 2022
SPRUCE BIOSCIENCES, INC.SPRB · Entity 6471DirectorJuly 22, 2025July 24, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

MBX Biosciences, Inc.

Report date June 04, 2026 · Filed June 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.91 · Expires 2036-06-04Direct12,500 Reported balance After 2026-06-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-04 · Grant · Acquired 12,500 · Balance 12,500

F1: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

Filing footnotes · ownership attribution and instrument terms

F1: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

Mirum Pharmaceuticals, Inc.

Report date July 17, 2019 · Filed July 17, 2019

This filing explicitly reported no securities owned.

Nkarta, Inc.

Report date June 08, 2022 · Filed June 10, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.95 · Expires 2032-06-07Direct16,000 Reported balance After 2022-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2022-06-08 · Grant · Acquired 16,000 · Balance 16,000

F1: All shares subject to the option vest 100% on the first to occur of (i) June 8, 2023 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement).

Filing footnotes · ownership attribution and instrument terms

F1: All shares subject to the option vest 100% on the first to occur of (i) June 8, 2023 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement).

SPRUCE BIOSCIENCES, INC.

Report date July 22, 2025 · Filed July 24, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.12 · Expires 2035-07-21Direct30,000 Reported balance After 2025-07-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2025-07-22 · Grant · Acquired 30,000 · Balance 30,000

F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

Filing footnotes · ownership attribution and instrument terms

F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

iRhythm Holdings, Inc.

Report date April 07, 2017 · Filed April 11, 2017

Section 16 reporting ended · disclosed 2017-04-11. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 04, 2026 Filed Jun 5, 2026 11:53 UTC MBX Biosciences, Inc. MBX · Entity 4247 GrantStock option (right to buy) · Derivative 12,500 $0.00 Strike: $30.91 $0.00
Disclosure

SEC source: 0001193125-26-258420 · ownership.xml · derivative · entry 1

Aynechi Tiba · CIK 0001669220 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

Read SEC document
July 22, 2025 Filed Jul 24, 2025 23:35 UTC SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $0.12 $0.00
Disclosure

SEC source: 0001415889-25-020266 · form4-07242025_110758.xml · derivative · entry 1

Aynechi Tiba · CIK 0001669220 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-07-21

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2026 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

Read SEC document
June 05, 2025 Filed Jun 6, 2025 12:05 UTC MBX Biosciences, Inc. MBX · Entity 4247 GrantStock option (right to buy) · Derivative 16,000 $0.00 Strike: $11.86 $0.00
Disclosure

SEC source: 0000950170-25-082703 · ownership.xml · derivative · entry 1

Aynechi Tiba · CIK 0001669220 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2035-06-05

F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

Read SEC document
September 16, 2024 Filed Sep 18, 2024 00:05 UTC MBX Biosciences, Inc. MBX · Entity 4247 ConversionSeries B Convertible Preferred Stock · Derivative 16,666,666 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-107525 · ownership.xml · derivative · entry 3

Aynechi Tiba · CIK 0001669220 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Norwest Venture Partners XVI, LP

Disclosed balance after: 0

Underlying: Common Stock · 1,386,335 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.

F1 · price: Each share of Series B Convertible Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.

F2 · ownership.nature: The securities are directly held by Norwest Venture Partners XVI, LP ("NVP XVI"). Genesis VC Partners XVI, LLC ("Genesis XVI") is the general partner of NVP XVI and NVP Associates, LLC ("NVP Associates") is the managing member of Genesis XVI. The Reporting Person, as an officer of NVP Associates and director of the Issuer, may be deemed to share voting and dispositive power over the shares held by NVP XVI and disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.

Read SEC document
September 16, 2024 Filed Sep 18, 2024 00:05 UTC MBX Biosciences, Inc. MBX · Entity 4247 PurchaseCommon Stock 750,000 $16.00 $12,000,000.00
Disclosure

SEC source: 0000950170-24-107525 · ownership.xml · nonDerivative · entry 2

Aynechi Tiba · CIK 0001669220 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Norwest Venture Partners XVI, LP

Disclosed balance after: 2,136,335

F3 · shares: Reflects shares purchased in the Issuer's initial public offering.

F2 · ownership.nature: The securities are directly held by Norwest Venture Partners XVI, LP ("NVP XVI"). Genesis VC Partners XVI, LLC ("Genesis XVI") is the general partner of NVP XVI and NVP Associates, LLC ("NVP Associates") is the managing member of Genesis XVI. The Reporting Person, as an officer of NVP Associates and director of the Issuer, may be deemed to share voting and dispositive power over the shares held by NVP XVI and disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.

Read SEC document
September 16, 2024 Filed Sep 18, 2024 00:05 UTC MBX Biosciences, Inc. MBX · Entity 4247 ConversionCommon Stock 1,386,335 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-107525 · ownership.xml · nonDerivative · entry 1

Aynechi Tiba · CIK 0001669220 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Norwest Venture Partners XVI, LP

Disclosed balance after: 1,386,335

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Convertible Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.

F2 · ownership.nature: The securities are directly held by Norwest Venture Partners XVI, LP ("NVP XVI"). Genesis VC Partners XVI, LLC ("Genesis XVI") is the general partner of NVP XVI and NVP Associates, LLC ("NVP Associates") is the managing member of Genesis XVI. The Reporting Person, as an officer of NVP Associates and director of the Issuer, may be deemed to share voting and dispositive power over the shares held by NVP XVI and disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.

Read SEC document
September 12, 2024 Filed Sep 13, 2024 21:04 UTC MBX Biosciences, Inc. MBX · Entity 4247 GrantStock Option (Right to Buy) · Derivative 15,963 $0.00 Strike: $16.00 $0.00
Disclosure

SEC source: 0000950170-24-106440 · ownership.xml · derivative · entry 1

Aynechi Tiba · CIK 0001669220 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,963

Underlying: Common Stock · 15,963 shares

Expires 2034-09-11

F1 · derivative.exercise_date: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Read SEC document
May 22, 2024 Filed May 24, 2024 20:23 UTC SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $0.75 $0.00
Disclosure

SEC source: 0001415889-24-014488 · form4-05242024_080531.xml · derivative · entry 1

Aynechi Tiba · CIK 0001669220 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-05-21

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2025 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

Read SEC document
May 25, 2023 Filed May 26, 2023 21:35 UTC SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $2.26 $0.00
Disclosure

SEC source: 0001209191-23-032650 · doc4.xml · derivative · entry 1

Aynechi Tiba · CIK 0001669220 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-05-24

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2024 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

Read SEC document
June 08, 2022 Filed Jun 10, 2022 20:03 UTC Nkarta, Inc. NKTX · Entity 6346 GrantStock Option (right to buy) · Derivative 16,000 $0.00 Strike: $14.95 $0.00
Disclosure

SEC source: 0001209191-22-035808 · doc4.xml · derivative · entry 1

Aynechi Tiba · CIK 0001669220 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2032-06-07

F1 · derivative.exercise_date: All shares subject to the option vest 100% on the first to occur of (i) June 8, 2023 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement).

Read SEC document
May 25, 2022 Filed May 27, 2022 20:19 UTC SPRUCE BIOSCIENCES, INC. SPRB · Entity 6471 GrantStock Option (Right to Buy) · Derivative 22,500 $0.00 Strike: $1.32 $0.00
Disclosure

SEC source: 0001209191-22-032525 · doc4.xml · derivative · entry 1

Aynechi Tiba · CIK 0001669220 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2023 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.